HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Mode of action of the novel phenazine anticancer agents XR11576 and XR5944.

Abstract
The substituted phenazines XR11576 and XR5944 were originally described as dual topoisomerase-I/II poisons. Subsequent reports, however, indicated that the association of their cytotoxicity with cellular topoisomerases was not clear. We set out to study this further using human tumour cell lines, PEO1 ovarian cancer, MDA-MB-231 breast cancer and variants with acquired resistance to VP-16 and XR11576: PEO1VPR, MB-231VPR, MB-231-11576R and camptothecin: PEO1CamR. Cytotoxicity testing [3-(4,5-dimethylthiazol-2yl)-2,5-diphenyl tetrazolium bromide assay], DNA-protein crosslink formation, cell cycle analysis (flow cytometry) for DNA content, apoptosis (flow cytometry) for Annexin V and Western blotting for apoptotic factors. Cytotoxicity testing showed potent cytotoxicity with no cross-resistance to XR11576 or XR5944 in VP-16 or camptothecin-resistant lines. Importantly, we have shown for the first time that the activities of XR5944 and XR11576 are similar as MB-231-11576R cells were resistant to both agents and to a similar extent. XR5944 showed the greatest, albeit slower, interaction with DNA with high levels of DNA-protein crosslinks. Levels of apoptosis in XR5944-treated cells were significantly less than those in VP-16 or XR11576 treatments, suggestive of a more cytostatic rather than cytotoxic mode of action. Interestingly, XR5944 failed to give rise to a G2/M blockade, in contrast to VP-16 or XR11576. XR5944 and XR11576, in line with a dual topoisomerase-I/II-directed mechanism of action, retain potent activity in tumour cells with acquired resistance to VP-16 and camptothecin. Although these agents appear to behave differently from each other according to experimental conditions, this study suggests a substantial overlap in their mechanism(s) of action.
AuthorsLouisa J Lewis, Prakash Mistry, Peter A Charlton, Hilary Thomas, Helen M Coley
JournalAnti-cancer drugs (Anticancer Drugs) Vol. 18 Issue 2 Pg. 139-48 (Feb 2007) ISSN: 0959-4973 [Print] England
PMID17159600 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • 4-methoxybenzo(a)phenazine-11-carboxylic acid (2-(dimethylamino)-1-methylethyl)amide
  • ATP-Binding Cassette Transporters
  • Annexin A5
  • Antineoplastic Agents
  • Antineoplastic Agents, Phytogenic
  • DNA, Neoplasm
  • Indicators and Reagents
  • Neoplasm Proteins
  • Phenazines
  • Topoisomerase I Inhibitors
  • XR5944
  • bcl-X Protein
  • Etoposide
  • Caspase 9
  • Camptothecin
Topics
  • ATP-Binding Cassette Transporters (metabolism)
  • Annexin A5 (metabolism)
  • Antineoplastic Agents (pharmacology)
  • Antineoplastic Agents, Phytogenic (pharmacology)
  • Apoptosis (drug effects)
  • Blotting, Western
  • Camptothecin (pharmacology)
  • Caspase 9 (metabolism)
  • Cell Cycle (drug effects)
  • Cell Line, Tumor
  • DNA, Neoplasm (chemistry)
  • Drug Resistance, Neoplasm
  • Etoposide (pharmacology)
  • Humans
  • Indicators and Reagents
  • Neoplasm Proteins (chemistry)
  • Phenazines (pharmacology)
  • Topoisomerase I Inhibitors
  • bcl-X Protein (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: